Download
-+ 0.00%
-+ 0.00%
-+ 0.00%
TELA Bio Q3 2026 net loss widens 8% year over year to $9.3 million; Q3 2026 revenue falls 8% year over year to $19 million
Share
Listen to the news
TELA Bio Q3 2026 net loss widens 8% year over year to $9.3 million; Q3 2026 revenue falls 8% year over year to $19 million
  • TELA Bio's third-quarter 2026 net loss widened 8% year over year to $9.3 million.
  • Revenue fell 8% year over year to $19 million, primarily due to lower OviTex PRS volumes, partially offset by international growth.
  • A strategic cost-reduction initiative targets $17 million in annual operating expense savings to extend cash runway into 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101600PRIMZONEFULLFEED9874727) on November 10, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending